Home » Stocks » AMYT

Amryt Pharma PLC (AMYT)

Stock Price: $13.75 USD -0.24 (-1.72%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 502.27M
Revenue (ttm) 182.61M
Net Income (ttm) -104.53M
Shares Out 35.76M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE 67.57
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $13.75
Previous Close $13.99
Change ($) -0.24
Change (%) -1.72%
Day's Open 13.99
Day's Range 13.50 - 13.99
Day's Volume 13,548
52-Week Range 10.06 - 15.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatmen...

1 week ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it hopes its gel designed to treat a rare skin disease will win fast-track approval from the US Food & Drug Administration after finishing the rolling compl...

2 weeks ago - Proactive Investors

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said has completed the rolling submission process that it hopes will end with the fast-track sign-off by the US Food & Drug Administration for its gel to treat a...

2 weeks ago - Proactive Investors

DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatme...

2 weeks ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it was ‘encouraged' by data from an investigator-sponsored study of lomitapide in Familial Chylomicronaemia Syndrome (FCS). Expert lipidologists in Italy ad...

2 weeks ago - Proactive Investors

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it was ‘encouraged' by data from an investigator-sponsored study of lomitapide in Familial Chylomicronaemia Syndrome (FCS). Expert lipidologists in Italy ad...

2 weeks ago - Proactive Investors

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said the European Union regulator will now begin the formal review process for its potential treatment for a rare genetic skin disorder with no currently approve...

2 weeks ago - Proactive Investors

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it has received positive feedback from the American drug regulator as it seeks sign-off for its Myalept drug for use in patients with partial lipodystrophy ...

3 weeks ago - Proactive Investors

Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy

3 weeks ago - GlobeNewsWire

Rare diseases specialist Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said the French authorities have signed off its drug Myalepta for reimbursement. The Ministry of Social Affairs and Health said it will ...

3 weeks ago - Proactive Investors

Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)

3 weeks ago - GlobeNewsWire

Amryt Pharma plc

1 month ago - GlobeNewsWire

Exercise of Options and Total Voting Rights

1 month ago - GlobeNewsWire

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights

1 month ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it has signed an agreement with Medison Pharma Canada, which will distribute the former's Myalepta drug in the country. It completes the multi-regional dist...

1 month ago - Proactive Investors

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

1 month ago - GlobeNewsWire

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year. The biopharma company,...

1 month ago - Proactive Investors

Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021

1 month ago - GlobeNewsWire

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

2 months ago - GlobeNewsWire

Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales

2 months ago - GlobeNewsWire

Amryt Granted Orphan Drug Designation by the FDA for AP103

3 months ago - GlobeNewsWire

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia

4 months ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

4 months ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

4 months ago - GlobeNewsWire

Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil

4 months ago - GlobeNewsWire

Amryt Announces $40m Private Placement with Leading Biotech Investors

4 months ago - GlobeNewsWire

AMRYT REPORTS RECORD Q3 2020 RESULTS

5 months ago - GlobeNewsWire

AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA

5 months ago - GlobeNewsWire

AMRYT PHARMA PLC

5 months ago - GlobeNewsWire

AMRYT PHARMA PLC

6 months ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

6 months ago - GlobeNewsWire

AMRYT PHARMA PLC

6 months ago - GlobeNewsWire

AMRYT PHARMA PLC

6 months ago - GlobeNewsWire

DUBLIN, Ireland, and Boston MA, July 8 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel...

9 months ago - GlobeNewsWire

About AMYT

Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2015
Stock Exchange
NASDAQ
Ticker Symbol
AMYT
Full Company Profile

Financial Performance

In 2020, Amryt Pharma's revenue was $182.61 million, an increase of 214.17% compared to the previous year's $58.12 million. Losses were -$104.53 million, 65.9% more than in 2019.

Financial Statements